# Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC

> **NCT03989115** · PHASE1,PHASE2 · COMPLETED · sponsor: **Revolution Medicines, Inc.** · enrollment: 113 (actual)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** RMC-4630
- **DRUG:** Cobimetinib
- **DRUG:** Drug: Osimertinib

## Key facts

- **NCT ID:** NCT03989115
- **Lead sponsor:** Revolution Medicines, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-07-02
- **Primary completion:** 2022-02-08
- **Final completion:** 2022-02-08
- **Target enrollment:** 113 (ACTUAL)
- **Last updated:** 2023-06-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03989115

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03989115, "Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT03989115. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*